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Abstract
Anti-angiogenic therapies have shown limited efficacy in the clinical management of metastatic disease, including
lung metastases. Moreover, the mechanisms via which tumours resist anti-angiogenic therapies are poorly
understood. Importantly, rather than utilizing angiogenesis, some metastases may instead incorporate pre-existing
vessels from surrounding tissue (vessel co-option). As anti-angiogenic therapies were designed to target only
new blood vessel growth, vessel co-option has been proposed as a mechanism that could drive resistance to
anti-angiogenic therapy. However, vessel co-option has not been extensively studied in lung metastases, and its
potential to mediate resistance to anti-angiogenic therapy in lung metastases is not established. Here, we examined
the mechanism of tumour vascularization in 164 human lung metastasis specimens (composed of breast, colorectal
and renal cancer lung metastasis cases). We identified four distinct histopathological growth patterns (HGPs) of
lung metastasis (alveolar, interstitial, perivascular cuffing, and pushing), each of which vascularized via a different
mechanism. In the alveolar HGP, cancer cells invaded the alveolar air spaces, facilitating the co-option of alveolar
capillaries. In the interstitial HGP, cancer cells invaded the alveolar walls to co-opt alveolar capillaries. In the
perivascular cuffing HGP, cancer cells grew by co-opting larger vessels of the lung. Only in the pushing HGP did
the tumours vascularize by angiogenesis. Importantly, vessel co-option occurred with high frequency, being present
in >80% of the cases examined. Moreover, we provide evidence that vessel co-option mediates resistance to the
anti-angiogenic drug sunitinib in preclinical lung metastasis models. Assuming that our interpretation of the data
is correct, we conclude that vessel co-option in lung metastases occurs through at least three distinct mechanisms,
that vessel co-option occurs frequently in lung metastases, and that vessel co-option could mediate resistance
to anti-angiogenic therapy in lung metastases. Novel therapies designed to target both angiogenesis and vessel
co-option are therefore warranted.
© 2016 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of Pathological Society of Great Britain and Ireland.
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any
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Introduction
Although the progression of metastases is considered
to require new blood vessel growth (angiogen-
esis), anti-angiogenic drugs have shown limited
efficacy in patients with metastatic disease. Metas-
tases can be either unresponsive to anti-angiogenic
therapy from the outset (intrinsic resistance) or
can develop resistance after an initial period of
response (acquired resistance). The mechanisms that
mediate this resistance are still poorly understood
[1–5].
However, rather than inducing angiogenesis, it now
emerges that some tumours can instead incorporate
pre-existing blood vessels from the surrounding normal
tissue, a process known as vessel co-option or vas-
cular co-option [5–7]. For example, seminal studies
on non-small-cell lung cancer (NSCLC) demonstrated
that some NSCLCs utilize vessel co-option instead
of angiogenesis [8–12]. In this ‘non-angiogenic’ sub-
type of NSCLC, the cancer cells grow only within
the alveolar air spaces. This permits intact alveolar
walls to be incorporated into the tumour, allowing
the tumour to co-opt the alveolar capillaries that are
contained within those alveolar walls [8–12]. A similar
presentation has been reported in some cases of human
lung metastasis [13–15]. In addition, we recently
examined the mechanism of tumour vascularization
in several preclinical models of lung metastasis. In
all models examined, the lung metastases co-opted
alveolar capillaries by occupying the alveolar air
spaces [16].
Given that conventional anti-angiogenic drugs were
designed only to inhibit angiogenesis, the presence
of vessel co-option in tumours may help to explain
the limited efficacy of conventional anti-angiogenic
therapies [7]. In support of this, vessel co-option has
now been implicated as a mechanism of resistance
to anti-angiogenic drugs in glioblastoma [17–19],
hepatocellular carcinoma [20], lymph node metas-
tases [21], liver metastases [22], and brain metastases
[23,24]. However, a role for vessel co-option in driving
therapy resistance in lung metastases has not been
reported.
In the current article, we describe three distinct
mechanisms of vessel co-option in human lung
metastases. We also quantify the incidence of ves-
sel co-option across a large series of human lung
metastasis cases. Finally, we utilize preclinical lung
metastasis models to investigate whether vessel
co-option can mediate resistance to anti-angiogenic
therapy.
Materials and methods
Human samples
Formalin-fixed paraffin-embedded samples of human
lung metastases were retrieved from archives at the St
Augustinus Hospital (Antwerp, Belgium), the Medical
University of Vienna (Vienna, Austria), and the National
Koranyi Institute of Pulmonology (Budapest, Hungary).
This initial series consisted of 193 lesions from 181
patients. Haematoxylin and eosin (H&E)-stained
sections were prepared from all cases for an initial
histopathological assessment. Twenty-nine lesions were
then excluded because they were unsuitable (supple-
mentary material, Figures S1–S3). The final series
analysed consisted of 164 lesions from 158 patients
(46 breast cancer metastases from 46 patients, 57
colorectal cancer metastases from 53 patients, and 61
renal cancer metastases from 59 patients). For patient
details, see supplementary material, Tables S1–S3.
Ethical approval was obtained from the Research Ethics
Committee of the GZA Hospitals St Augustinus, the
Ethics Committee of the Medical University of Vienna,
and the National Scientific and Ethics Committee of
Hungary.
Staining of tissue sections, histopathological
analysis, and preclinical models
Details of the procedures that were used for tissue stain-
ing, scoring of histopathological growth patterns, scor-
ing of breast cancer subtypes (which were determined
as per published guidelines [25–27]) and in vivomodels
can be found in supplementary material, Supplementary
materials andmethods. The Institute of Cancer Research
Animal Ethics Committee granted approval for animal
work, and procedures were performed in accordance
with the UK Home Office regulations.
Statistical analysis
Statistical analysis was performed with a two-tailed
Fisher’s exact test or a two-tailed Student’s t-test.
P-values of <0.05 were considered to be significant.
Results
Human lung metastases present with distinct
growth patterns that are associated with different
vascularization mechanisms
To investigate the mechanisms of tumour vascular-
ization in human lung metastases, we performed a
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histopathological analysis on 164 human lung metas-
tasis cases (46 breast cancer metastases, 57 colorec-
tal cancer metastases, and 61 renal cancer metastases).
We identified four distinct histopathological growth pat-
terns (HGPs): the alveolar HGP, the interstitial HGP,
the perivascular cuffing HGP, and the pushing HGP.
We present evidence that, although pushing HGP lung
metastases utilize angiogenesis, tumour vascularization
occurs through vessel co-option in the alveolar, intersti-
tial and perivascular cuffing HGPs.
Co-option of alveolar capillaries in the alveolar HGP
In previous studies, incorporation of intact alveolar walls
into lung metastases has been cited as evidence that
these tumours co-opt pre-existing alveolar capillaries
[13,14,16]. In order to robustly identify the presence
of alveolar walls in human tissue specimens, we per-
formed staining for the established pneumocyte marker
cytokeratin (CK) 7 [28]. In normal human lung, CK7
staining demonstrated a network of CK7-positive alve-
olar walls separated by intervening alveolar air spaces
(Figure 1A). This ‘honeycomb’ morphology is charac-
teristic of normal human lung parenchyma. Staining for
a second established pneumocyte marker, thyroid tran-
scription factor 1 [29], gave similar results.
We then performed staining for pneumocytes in sam-
ples of human breast cancer lung metastases. This
approach clearly demonstrated two of the growth pat-
terns of human lung metastases: the alveolar HGP and
the pushing HGP. In the alveolar HGP, the cancer cells
at the periphery of the metastasis entered the alveolar
air spaces of the lung, which led to the incorporation of
intact alveolar walls into the tumour (Figure 1C). In con-
trast, in the pushing HGP, the cancer cells did not enter
the alveolar air spaces. Instead, the alveolar walls at the
periphery of the metastases were pushed away by the
tumour (Figure 1E).
Additionally, we examined blood vessels by staining
for the vascular endothelial marker CD31. In normal
human lung, a honeycomb network of CD31-positive
alveolar walls, separated by intervening alveolar air
spaces, was observed (Figure 1B). Importantly, inmetas-
tases with an alveolar HGP, the tumour vessel architec-
ture closely resembled the vascular architecture of the
normal lung (Figure 1D), suggesting that these tumours
do co-opt pre-existing alveolar capillaries by grow-
ing within the alveolar air spaces [8–10,13]. However,
in sharp contrast, pushing HGP metastases contained
abnormal and chaotically organized vessels (Figure 1F),
which is typical of vessels generated by tumour angio-
genesis [8–10,13]. Equivalent growth patterns were
observed in both colorectal cancer and renal cancer lung
metastases (supplementarymaterial, Figures S4 and S5).
Our interpretation of these data is that, whereas alveolar
HGP lung metastases utilize vessel co-option to obtain
a vascular supply, pushing HGP lung metastases utilize
angiogenesis.
To further characterize the mechanism of vessel
co-option, lung metastases were co-stained for CK7
and CD31. In normal lung, this staining demonstrated
the architecture of the normal alveolar walls, which
are lined by CK7-positive pneumocytes and contain
CD31-positive alveolar capillaries (Figure 2A). At the
tumour–lung interface of alveolar HGP metastases,
cancer cells invaded into the air spaces, facilitating the
co-option of CD31/CK7-positive alveolar walls into the
metastases (Figure 2B). Just behind the tumour–lung
interface, the alveolar air spaces were fully occupied by
cancer cells, but the co-opted CD31/CK7-positive alve-
olar walls remained intact (Figure 2C; supplementary
material, Figure S6A–C). Co-opted alveolar capillar-
ies often contained erythrocytes, confirming that the
co-opted blood vessels were perfused (supplementary
material, Figure S6D, E).
Moving towards the centre of the metastases,
CD31-positive alveolar capillaries could be found that
were now only partially associated with CK7-positive
pneumocytes, suggesting that alveolar epithelium
is gradually lost from co-opted alveolar capillaries
(Figure 2D). To further corroborate this, alveolar HGP
lung metastases stained for CK7 were viewed at low
power. Whereas pneumocyte-rich alveolar walls were
incorporated at the periphery of the metastases, a
gradual loss of pneumocytes towards the centre of the
metastases was evident (supplementary material, Figure
S7). Our interpretation of these data is that cancer cells
first co-opt alveolar walls by invading the alveolar air
spaces and that, subsequently, pneumocytes are gradu-
ally lost from these co-opted alveolar walls. However,
after loss of these pneumocytes, the co-opted alveolar
capillaries are retained by the tumour. In contrast, in
pushing HGP lung metastases, we found no incorpora-
tion of alveolar walls into the tumour, suggesting that
pushing HGP lung metastases do not co-opt alveolar
capillaries (Figure 2E, F).
Co-option of alveolar capillaries in the interstitial
HGP
In this study, we also observed a second growth pattern
via which human lung metastases may co-opt alveo-
lar capillaries. In the interstitial HGP, cancer cells were
seen to co-opt alveolar capillaries by growing within
the alveolar walls of the lung. The interstitial HGP is
illustrated here with a case of renal cancer lung metas-
tasis (Figure 3). Co-staining for carbonic anhydrase 9
(CAIX), to detect renal cancer cells, and CK7, to detect
pneumocytes, demonstrated the infiltration of cancer
cells into the normal alveolar walls at the tumour–lung
interface (Figure 3A). To verify that this mode of infil-
trative growth permits co-option of alveolar capillaries,
co-staining for CAIX and CD31 was utilized. Close
inspection of the alveolar walls at the tumour–lung
interface demonstrated thin columns of cancer cells
invading through the alveolar interstitium between the
pre-existing alveolar capillaries (Figure 3B). Our inter-
pretation of these data is that cancer cells can also invade
through the alveolar walls to facilitate the co-option of
alveolar capillaries.
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Figure 1. Alveolar and pushing growth patterns of human lung metastases. (A, B) Normal human lung parenchyma, stained for CK7 (A) or
CD31 (B). (C, D) Alveolar HGP of human breast cancer lung metastasis. Staining for CK7 (at the tumour–lung interface) is shown in (C).
Staining for CD31 (within the tumour) is shown in (D). (E, F) Pushing HGP of human breast cancer lung metastasis. Staining for CK7 (at the
tumour–lung interface) is shown in (E). Staining for CD31 (within the tumour) is shown in (F). Cancer cells: asterisks. Alveolar macrophages:
arrows. Alveolar air space: air. Tumour–lung interface: dashed line. Normal lung: lu. Scale bar: 50 μm.
Just behind the tumour–lung interface, CAIX-
positive cancer cells completely filled the alveolar
walls, but the intervening alveolar air spaces were
preserved (Figure 3C). Importantly, these cancer-filled
alveolar walls contained an abundance of co-opted
alveolar capillaries (Figure 3D). Deeper into the metas-
tasis, expansion of the cancer cell population resulted
in significant broadening of the alveolar walls, but
the intervening alveolar air spaces were mostly still
preserved (Figure 3E). Some invasion of cancer cells
into the alveolar air spaces was, however, also detected
in the centre of the metastasis (Figure 3E). Within the
metastasis, we often observed blood vessels that were
closely associated with the abluminal side of the air
spaces (Figure 3F). If our interpretation of the data is
correct, the close association of these particular vessels
with pneumocytes, deep within the metastasis, indicates
that these are co-opted alveolar capillaries rather than
newly formed vessels. However, we cannot completely
rule out the possibility that angiogenesis also occurs
in this growth pattern, especially in the centre of the
metastasis. We named this growth pattern the interstitial
HGP because of the propensity for cancer cells to grow
within the alveolar interstitium, and to be consistent
with a previous report of a similar growth pattern [14].
Co-option of large blood vessels in the perivascular
cuffing HGP
Thus far, we have described two mechanisms via which
cancer cells co-opt alveolar capillaries. However, the
lungs also contain larger vessels (i.e. arteries and veins)
that are distinct from alveolar capillaries because of
their larger calibre and because they are surrounded by
© 2016 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd J Pathol 2017; 241: 362–374
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Figure 2. Vessel co-option occurs in the alveolar growth pattern of human lung metastases. (A–D) Immunofluorescence co-staining for
CD31 (red) and CK7 (green) in a case of human breast cancer lung metastasis that presented with an alveolar HGP. (A) In areas of
tumour-free normal lung parenchyma, the alveolar walls are composed of CD31-positive alveolar capillaries (red) that are sheathed by
CK7-positive pneumocytes (green). (B) At the tumour–lung interface, cancer cells (asterisks) invade an alveolar air space. Arrowheads
indicate two CD31-positive alveolar macrophages in the alveolar air space that also reacted with the CD31 antibody. (C) Behind the
tumour–lung interface, cancer cells (asterisks) completely fill the alveolar air spaces, preserving the alveolar walls and the associated
alveolar capillaries. (D) Towards the centre of the metastatic lesion, co-opted alveolar capillaries can be found that are only partially
coated by pneumocytes. Arrows indicate pneumocytes that are still associated with co-opted alveolar capillaries. Arrowheads indicate
autofluorescent erythrocytes in the lumen of co-opted alveolar capillaries. (E, F) Immunofluorescence co-staining for CD31 (red) and CK7
(green) in a sample of human renal cancer lung metastasis with a pushing HGP. At the tumour–lung interface, cancer cells push the alveolar
walls away (E). No incorporation of alveolar walls was observed either at the tumour–lung interface (E) or deeper into the metastasis (F).
Alveolar air space: air. Normal lung: lung. Scale bar: 25 μm.
© 2016 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd J Pathol 2017; 241: 362–374
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Figure 3. Vessel co-option occurs in the interstitial growth pattern of human lung metastases. Immunohistochemical analysis of a renal
cancer lung metastasis with an interstitial HGP, illustrating growth of cancer cells within the alveolar walls. Staining for CAIX (brown) was
used to detect cancer cells, in combination with either CK7 staining (green) to detect pneumocytes (A, C, E) or CD31 staining (green) to detect
blood vessels (B, D, F). (A) Tumour–lung interface: alveolar walls filled with cancer cells are present at the top of the image (asterisks),
whereas tumour-free alveolar walls of the normal lung are present below (diamond symbols). (B) High-power view of an alveolar wall
(delineated with a dashed line). Asterisks indicate cancer cells that are infiltrating around pre-existing alveolar capillaries. (C, D) The area
just behind the tumour–lung interface: the alveolar walls are now completely filled with cancer cells. The intervening alveolar air spaces
remain intact. (E, F) The centre of the metastasis. In (E), asterisks indicate cancer cells that are filling the expanded alveolar walls, while the
intervening alveolar air spaces remain intact. The arrow indicates an alveolar air space that has become partially filled with cancer cells.
In (F), arrowheads indicate blood vessels that are closely associated with the abluminal side of an alveolar air space. Alveolar air space: air.
Scale bars: 100 μm (A, C, D, E, F) and 50 μm (B).
a layer of smooth muscle cells (the tunica media) (sup-
plementary material, Figure 8A, B). In the perivascular
cuffing HGP of human lung metastases, the cancer cells
grow exclusively like a cuff around these larger vessels
(supplementary material, Figure 8C–F). The cuff can
be several layers of cancer cells thick, but is devoid of
additional blood vessels. Our interpretation of these data
is that the cancer cells utilize the central co-opted vessel
as their principal vascular supply in this growth pattern.
Frequency of the different growth patterns
in human lung metastases
To evaluate the frequencies of the alveolar, interstitial,
perivascular cuffing and pushing HGPs in human lung
metastases, all 164 cases were scored for their HGP
(Figure 4A–C). It is of note that some lesions pre-
sented withmore than one growth pattern. Therefore, the
percentage of the tumour–lung interface adopting each
growth pattern was scored in intervals of 5%.
To formally analyse the prevalence of vessel co-option
across the different tumour types, growth patterns that
utilize vessel co-option (alveolar, interstitial, and
perivascular cuffing) were pooled together, and their
incidence was compared with the incidence of the
angiogenic pushing growth pattern. Vessel co-opting
growth patterns were present to some extent (≥5% of
the tumour–lung interface) in 91.3% of breast, 98.2%
of colorectal and 62.3% of renal cancer metastases.
© 2016 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd J Pathol 2017; 241: 362–374
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Figure 4. Frequency of the different HGPs in lung metastases of human breast, colorectal and renal cancer. Lung metastases of human
breast cancer (A), human colorectal cancer (B) and human renal cancer (C) were scored for their growth pattern. Each bar represents an
individual case of metastasis showing the percentage of the tumour–lung interface scored as alveolar, interstitial, perivascular cuffing
or pushing HGP. n= 46 breast cancer lung metastases (A), n= 57 colorectal cancer lung metastases (B), and n= 61 renal cancer lung
metastases (C).
Moreover, vessel co-opting growth patterns were dom-
inant (≥75% of the tumour–lung interface) in 71.7%
of breast, 78.9% of colorectal and 37.7% of renal
cancer metastases. Vessel co-opting growth patterns
were more common in breast cancer than in renal cancer
(p= 0.0008, Fisher’s exact test), and in colorectal cancer
than in renal cancer (p< 0.0001, Fisher’s exact test).
Breast cancer metastases were also characterized
for intrinsic molecular subtype: luminal A, lumi-
nal B (HER2-negative), luminal B (HER2-positive),
HER2-positive (non-luminal), and triple-negative. Ves-
sel co-opting growth patterns were present across all
subtypes (supplementary material, Figure S9). However,
vessel co-option was less prevalent in triple-negative
tumours than in other subtypes (p= 0.022, Fisher’s
exact test).
Limited efficacy of sunitinib in lung metastasis
models as compared with subcutaneously
implanted tumours
Conventional anti-angiogenic therapies were designed
to inhibit new blood vessel growth, but were not
designed to target vessel co-option. To investigate
whether vessel co-option could mediate resistance to
anti-angiogenic therapy in lung metastases, we utilized
three preclinical syngeneic tumour models correspond-
ing to the three types of human cancer studied above.
© 2016 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd J Pathol 2017; 241: 362–374
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The 4 T1 cell line was used to model breast cancer,
and the C26 and RENCA cell lines were used to model
colorectal and renal cancer, respectively. To examine
the response to anti-angiogenic therapy, we utilized
the potent anti-angiogenic tyrosine kinase inhibitor
sunitinib.
As the growth of subcutaneously implanted tumours
is known to be angiogenesis-dependent, we first
assessed sunitinib activity against subcutaneously
implanted 4 T1, C26 and RENCA tumours. Treatment
with 40mg/kg per day sunitinib for 10 days significantly
suppressed both tumour vessel density and tumour bur-
den in all three models (Figure 5A–C), confirming the
ability of sunitinib to suppress tumour angiogenesis and
tumour growth in these three angiogenesis-dependent
tumour models.
We then investigated the response to sunitinib in lung
metastases formed by the same cell lines. Lung metas-
tases were established by intravenous tail vein injection
of 4 T1, C26 or RENCA cells. In contrast to its potent
activity against subcutaneously implanted tumours, the
same sunitinib treatment regimen (40mg/kg per day
sunitinib for 10 days) did not significantly suppress
tumour vessel density in any of the lung metastasis
models (Figure 5D–F). In addition, sunitinib treatment
did not reduce tumour burden in either 4 T1 or C26
lung metastases (Figure 5D, E). Sunitinib treatment
did significantly suppress tumour burden by ∼34% in
RENCA lung metastases (Figure 5F). However, this
activity is modest when compared with subcutaneously
implanted RENCA tumours, in which the same treat-
ment regimen suppressed tumour burden by ∼80%
(Figure 5C).
Evidence that vessel co-option mediates resistance
to sunitinib in 4 T1 and C26 lung metastases
To determine why the lung metastases responded so
poorly to this anti-angiogenic drug, we examined the
histopathological growth patterns of all three lung
metastasis models (Figure 6). 4 T1 and C26 lung metas-
tases had irregular margins and were highly infiltrative
into the lung parenchyma (Figure 6A, E). Closer exam-
ination revealed that the cancer cells colonized the
lung by growing in the alveolar air spaces and/or by
growing in the alveolar walls (supplementary mate-
rial, Figure S10). Staining for the pneumocyte marker
CK7 revealed that the alveolar walls of the lung were
clearly incorporated into the metastases (Figure 6B, F).
Moreover, co-staining for CK7 and the blood vessel
marker CD34 highlighted the presence of blood vessels
in these tumours that were still associated with alveolar
epithelial cells, showing that these tumours incorporate
alveolar capillaries (Figure 6C, G). Therefore, the 4 T1
and C26 models have a growth pattern that mimics
the alveolar/interstitial HGP of human lung metas-
tases, and these tumours co-opt pre-existing alveolar
capillaries. Quantification of the growth pattern in
4 T1 and C26 lung metastases revealed that this alve-
olar/interstitial HGP was the dominant growth pattern
in both the vehicle-treated and sunitinib-treated mice
(Figure 6D, H).
Our interpretation of these data is that the 4 T1 and
C26 models of lung metastasis co-opt pre-existing alve-
olar capillaries, and that these co-opted vessels are not
sensitive to sunitinib treatment. These data provide a
potential mechanistic explanation for the inability of
sunitinib to control tumour burden in these lung metas-
tasis models.
Evidence that a switch from angiogenesis to vessel
co-option mediates resistance to sunitinib
in RENCA lung metastases
The situation was more complex for RENCA lung
metastases, which presented with a mixture of pushing
HGP metastases (Figure 6I–K) and alveolar/interstitial
HGP metastases (Figure 6L–N). In vehicle-treated
mice, the pushing HGP was the prevalent growth pat-
tern of RENCA lung metastases (Figure 6O). These
pushing HGP metastases had a strikingly spherical or
‘cannonball’ shape (Figure 6I), and, instead of invading
the lung parenchyma, these tumours pushed the alveolar
walls away (Figure 6J). The blood vessels in pushing
HGP metastases were not associated with CK7-positive
pneumocytes, suggesting that these tumours vascular-
ize through angiogenesis instead of vessel co-option
(Figure 6K).
However, in sunitinib-treated mice, the alveo-
lar/interstitial HGP was the prevalent growth pattern
of RENCA lung metastases (Figure 6O). RENCA lung
metastases with an alveolar/interstitial HGP had an
irregular margin and infiltrated the lung parenchyma
(Figure 6L). Staining for CK7 revealed incorporation
of alveolar walls into the metastases (Figure 6M), and
co-staining for CD34 and CK7 highlighted that these
tumours incorporate pre-existing alveolar capillaries
(Figure 6N).
In the analysis of vessel density in RENCA lung
metastases described above (Figure 5F), vessel den-
sity was quantified across the entire tissue section
without regard to the growth pattern. We therefore
re-examined vessel density in RENCA lung metas-
tases by quantifying, separately, the vessel density in
pushing HGP lesions and the vessel density in alveo-
lar/interstitial HGP lesions. Importantly, whereas vessel
density was significantly lower in pushing HGPRENCA
lesions from sunitinib-treated mice than in the vehi-
cle group (supplementary material, Figure S11A–C),
no significant difference in vessel density was observed
between alveolar/interstitial HGP RENCA lesions from
sunitinib-treated mice and the vehicle group (supple-
mentary material, Figure S11D–F).
Our interpretation of these data is that: [1] the vessels
of angiogenic pushing growth pattern RENCA lung
metastases are sensitive to sunitinib; and [2] sunitinib
also induces a rapid shift in growth pattern to the alve-
olar/interstitial HGP, which permits the co-option of
alveolar capillaries that are resistant to sunitinib. This
provides a potential mechanistic explanation for why
© 2016 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd J Pathol 2017; 241: 362–374
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Figure 5. Limited efficacy of sunitinib in lung metastasis models as compared with subcutaneously implanted tumours. (A–C) The efficacy
of sunitinib was tested in mice injected subcutaneously with 4 T1 (A), C26 (B) or RENCA (C) cells. The graphs show tumour vessel
density± standard error of the mean (SEM) (left) or tumour burden± SEM (right) in subcutaneous 4 T1 (A), C26 (B) or RENCA (C) tumours
after 10 days of treatment with either 40mg/kg per day sunitinib or vehicle alone. n= 10 mice per experimental group for tumour burden
graphs. n= 6 mice per experimental group for tumour vessel density graphs. (D–F) Mice were injected via the tail vein with 4 T1 (D), C26
(E) or RENCA (F) cells. The graphs show tumour vessel density± SEM (left) or tumour burden± SEM (right) in the lungs after 10 days of
treatment with either 40mg/kg per day sunitinib or vehicle alone. n= 9 or 10 mice per experimental group for tumour burden graphs. n= 5
mice per experimental group for tumour vessel density graphs. ns, no significant difference; sun, sunitinib; veh, vehicle.
sunitinib has only a modest effect on tumour burden in
the RENCA lung metastasis model.
Discussion
Here, we examined the mechanisms of tumour vascu-
larization in human lung metastases. We report three
distinct growth patterns of human lung metastases in
which, if our interpretation of the histology is cor-
rect, the co-option of pre-existing vessels occurs via
three distinct mechanisms. In the alveolar HGP, can-
cer cells invade the alveolar air spaces, which facilitates
the co-option of the alveolar capillaries that lie within
the incorporated alveolar walls. In the interstitial HGP,
cancer cells infiltrate the alveolar walls, which again
allows the co-option of alveolar capillaries, albeit via a
mechanism that is distinct from that in the alveolar HGP.
In the perivascular cuffing HGP, cancer cells grow as
a cuff around large pre-existing vessels of the lung,
resulting in the co-option of these larger vessels. We
also report a pushing HGP in which the lung metas-
tases present with a chaotically organized vasculature
that is typical of tumour angiogenesis. Our interpreta-
tion of these data is that lung metastases can vascularize
by co-opting pre-existing vessels of the lung (via three
distinct mechanisms) or can utilize angiogenesis. More-
over, rather than being a rare event, we found that vessel
co-option occurs frequently in human lung metastases.
We do acknowledge, however, that both angiogenesis
and vessel co-option can occur within the same lesion.
In support of this, we observed here that lung metas-
tases can present with a mixture of growth patterns e.g.
lesions in which the pushing HGP and the alveolar HGP
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Figure 6. Evidence for vessel co-option in lung metastasis models. Histopathological characterization was performed on lung metastases
formed by 4 T1 cells (A–D), C26 cells (E–H) and RENCA cells (I–O) after tail vein injection. (A, E, I, L) Low-power views of lung metastasis
morphology by H&E staining. (B, C, E, F, I, J, L, M) Higher-power views of CK7-stained lung metastases (B, F, J, M) or lung metastases
co-stained for CD34 (red) and CK7 (green) (C, G, K, N). The graphs show percentage alveolar/interstitial HGP and percentage pushing HGP
scored in 4 T1 (D), C26 (H) and RENCA (O) lung metastases from vehicle (veh)-treated or sunitinib (sun)-treated mice (n= 9 or 10 mice per
experimental group). Cancer cells: asterisks. Alveolar air spaces: air. ns, no significant difference. Scale bars: 125 μm (A, E, I, L), 20 μm (B, F,
J, M) and 20 μm (C, G, K, N).
were both present, but in different areas of the same
lesion.Moreover, in both the alveolar HGP and the inter-
stitial HGP, it is possible that new vessels can sprout
from co-opted vessels once the co-opted vessels are in
the centre of the metastasis. In support of this, studies
on NSCLC have shown that many of these tumours can
invade the alveolar air spaces at the tumour periphery
(permitting vessel co-option), but that a switch to angio-
genesis then occurs in the centre of the tumour [8,9].
Presumably, this occurs because vessels co-opted at the
periphery are induced to undergo angiogenesis when
they find themselves within the centre of the tumour. We
therefore propose that there is both spatial heterogeneity
and temporal heterogeneity in the vascularization mech-
anisms used by human tumours, with lesions being able
to utilize either angiogenesis or vessel co-option or both.
It is not currently clear why cancer cells utilize vessel
co-option instead of, or as well as, activating angiogen-
esis when they metastasize to the lung. Previous work
has suggested that, although micrometastases can rely
on vessel co-option, tumours must switch to a reliance
on angiogenesis as they become larger [30]. How-
ever, in the current study, we observed vessel co-option
even in human lung metastases that were large (≥1 cm
in diameter). If we interpret these data correctly, we
must conclude that vessel co-option can be a mecha-
nism of tumour vascularization in both micrometastases
and macrometastases. In addition, our data suggest that
tumours of diverse primary origin (i.e. breast, bowel, and
kidney) can all utilize vessel co-option when theymetas-
tasize to lung. Given this evidence, it seems probable
that the environment of the lung plays an active role in
inducing cancer cells to utilize vessel co-option instead
of angiogenesis.
We also provide evidence that vessel co-option
mediates intrinsic resistance to anti-angiogenic therapy
in preclinical lung metastasis models. Whereas the
anti-angiogenic drug sunitinib suppressed the growth
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of angiogenesis-dependent subcutaneously implanted
4 T1 and C26 tumours, the lung metastases of 4 T1
and C26 tumours utilized vessel co-option and showed
intrinsic resistance to this same anti-angiogenic drug.
Further evidence that vessel co-option mediates intrin-
sic resistance to anti-angiogenic therapy comes from a
spontaneous breast cancer metastasis model using the
highly metastatic MDA-MB-231LM2–4 breast cancer
cell line. We reported previously that, whereas the
growth of MDA-MB-231LM2–4 tumours is significantly
suppressed by sunitinib when these cells are implanted
orthotopically in the mammary fat pad, administration
of sunitinib does not prolong the survival of mice
bearing spontaneous MDA-MB-231LM2–4 metastases
[31]. Importantly, we found that, whereas mammary
fat pad-implanted MDA-MB-231LM2–4 tumours are
angiogenic, spontaneous MDA-MB-231LM2–4 lung
metastases utilize vessel co-option (Harold Dvorak and
Robert Kerbel, unpublished observation). In confirma-
tion of this, staining for CK7 and CD34 in spontaneous
MDA-MB-231LM2–4 lung metastases demonstrated
that these tumours have an alveolar HGP and that they
do co-opt alveolar capillaries (supplementary material,
Figure S12). If our interpretation of these data is correct,
vessel co-option is therefore associated with intrinsic
resistance to sunitinib, not just in intravenous models of
lung metastasis (i.e. 4 T1 and C26), but also in a model
of spontaneous breast cancer lung metastasis using a
human breast cancer cell line (i.e. MDA-MB-231LM2–4).
Vessel co-option might also mediate acquired resis-
tance to anti-angiogenic therapy. Although RENCA
lung metastases presented mainly as angiogenic push-
ing HGP lesions in vehicle-treated mice, sunitinib
induced a switch to an alveolar/interstitial HGP that
vascularizes by vessel co-option. Importantly, whereas
the vessels of pushing HGP metastases were sensi-
tive to sunitinib, the vessels of alveolar/interstitial
HGP lung metastases were not. Our interpretation of
these data is that a treatment-induced switch from
angiogenesis to vessel co-option could drive acquired
resistance to anti-angiogenic therapy. In further support
of this, Kuczynski et al recently showed that a switch
from angiogenesis to vessel co-option drives acquired
resistance to the anti-angiogenic drug sorafenib in
hepatocellular carcinoma [20]. Moreover, a switch from
angiogenesis to vessel co-option has been reported
to occur in some brain malignancies treated with
anti-angiogenic therapy [17–19,23,24].
Four phase 3 trials have tested sunitinib in metastatic
breast cancer, with no benefit in either progression-free
survival (PFS) or overall survival (OS) being demon-
strated for sunitinib [32–35]. If the quantification of
vessel co-option in human breast cancer lung metas-
tases presented here is representative of breast cancer
patients as a whole, many patients entering these trials
will have presented with breast cancer metastases to the
lung that vascularize through vessel co-option. In addi-
tion, vessel co-option occurs in breast cancer metastases
to the skin [36], lymph nodes [21,37], liver [22,38], and
brain [39–41]. Therefore, vessel co-option may help to
explain, at least in part, why anti-angiogenic therapy has
been a disappointing therapeutic approach in metastatic
breast cancer.
In contrast to its effect on breast cancer, sunitinib
extends both PFS and OS in metastatic renal cancer
[42,43]. Here, we found that vessel co-option occurs
less frequently in human renal cancer lung metastases
than in human breast cancer lung metastases. This dis-
parity may help to explain why sunitinib is a clinically
more effective treatment for metastatic renal cancer than
for metastatic breast cancer. Nonetheless, both intrinsic
and acquired resistance to anti-angiogenic drugs occur
in renal cancer patients [44,45].Moreover, despite show-
ing activity in the advanced disease setting, sunitinib did
not prolong disease-free survival in renal cancer patients
who received this drug as adjuvant therapy [46]. We pro-
pose that vessel co-option may help to explain resistance
to anti-angiogenic therapy of renal cancer in both the
metastatic setting and the adjuvant setting.
In conclusion, if we have interpreted our data cor-
rectly, vessel co-option is a common event in human
lung metastases that occurs via three distinct mecha-
nisms. Moreover, our data suggest that vessel co-option
may drive resistance to anti-angiogenic therapy in pre-
clinical lung metastasis models. One limitation of our
study is that, owing to a lack of sufficient lung metasta-
sis samples from patients treated with anti-angiogenic
therapy, we have not been able to examine whether
there is an association between vessel co-option and
resistance to anti-angiogenic therapy in patients. There
are, however, clinical data showing that co-option of
the pre-existing vasculature is associated with resistance
to anti-angiogenic therapy in both lymph node metas-
tases [21] and liver metastases [22]. Further research
is therefore now warranted to confirm the role of ves-
sel co-option in resistance to anti-angiogenic therapy in
patients with lung metastases.
If vessel co-option does prove to be a common mech-
anism of resistance to anti-angiogenic therapy across
multiple metastatic sites, then therapeutic approaches
that can inhibit both angiogenesis and vessel co-option
may bewarranted for the treatment ofmetastatic disease.
However, further research will now be required to estab-
lish how both modalities of tumour vascularization can
be effectively targeted simultaneously in patients.
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